Trial · NCT02964572
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | changes in the secretion of IL-1 beta from peripheral blood mononuclear cells | Day 60 | The effect of empagliflozin on the secretion of IL-1beta from peripheral blood mononuclear cells |
| Secondary | Changes in the secretion of TNF-alpha from peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of beta-hydroxybutyrate, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in body weight (kg), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of insulin (µU/mL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of glucagon (pg/mL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of free fatty acid (μEq/L), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum glycated albumin (%), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of glucose (mg/dL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of uric acid (mg/dL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of liver enzymes (aspartate aminotransferase and alanine aminotransferase (IU/L)), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol (mg/dL)), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in serum concentrations of creatinine (mg/dL), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in spot urine concentrations of glucose (mg/dL) and creatinine (mg/dL) (those will be combined to report spot urine glucose-to-creatinine ratio in mg/mg), before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in mRNA expression level (PCR, fold) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days | |
| Secondary | Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride | Day 60 plus or minus 32 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964572/registered